NCT01804634 2026-03-13
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
Clinical Trials
8 trialsNCT05046314 2026-01-14
A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 2 Recruiting
NCT05135975 2025-08-12
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
Nationwide Children's Hospital
Phase 2 Recruiting
NCT06827717 2025-05-31
Phase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing Sarcoma
Sun Yat-sen University
Phase 2 Recruiting
NCT05968768 2025-04-10
To Evaluate the Efficacy and Safety of Naxitamab in Patients With Refractory Ewing's Sarcoma (Butterfly)
Institute of Mother and Child, Warsaw, Poland
Phase 2 Recruiting
NCT06699472 2024-11-21
A Prospective, Randomized, Controlled Clinical Study on the Prevention of Chemotherapy Related Myelosuppression in Patients with Ewing's Sarcoma Using Trilaciclib
Fudan University
Phase 2 Recruiting
NCT06564272 2024-08-23
A Study of KC1036 in Adolescents With Advanced Ewing Sarcoma
Beijing Konruns Pharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT04758000 2023-08-04
Metform-Bone
Istituto Ortopedico Rizzoli
Phase 2 Recruiting